Miltefosine

Miltefosine structure

Miltefosine is a pharmaceutical agent primarily prescribed for the treatment of leishmaniasis and specific free-living amoeba infections. Marketed under the brand name Impavido among other labels, this drug has revolutionized the treatment of some challenging parasitic diseases, particularly within the tropical disease domain.

Indications[edit]

Miltefosine has shown therapeutic benefits against a spectrum of parasitic infections:

Leishmaniasis: The drug combats all three clinical manifestations of this condition:

- Cutaneous leishmaniasis^[1]
- Visceral leishmaniasis^[2]
- Mucosal leishmaniasis

Free-Living Amoeba Infections:

- Naegleria fowleri: A rare, but often fatal, brain infection^[3].
- Balamuthia mandrillaris: An amoeba that affects the skin and the central nervous system.

In certain scenarios or for particular patient demographics, Miltefosine might be prescribed alongside other antiparasitic treatments, such as liposomal amphotericin B or paromomycin.

Administration[edit]

Administered orally, Miltefosine offers a preferable alternative to the often cumbersome intravenous or intramuscular treatments generally prescribed for parasitic afflictions.

Mechanism of Action[edit]

While ongoing research is still demystifying its exact mechanism, existing evidence suggests that Miltefosine disrupts the cellular metabolism of parasites, halting their growth and proliferation^[4].

Adverse Effects[edit]

Like many drugs, Miltefosine has associated side effects that can range from mild to severe:

Common:

- Vomiting
- Abdominal pain
- Fever
- Headaches
- Impaired kidney function

Severe:

- Stevens-Johnson syndrome: A severe dermatological reaction.
- Thrombocytopenia: A condition characterized by reduced blood platelet count^[5].

Contraindications[edit]

Pregnant individuals should refrain from Miltefosine due to documented teratogenic effects on the fetus^[6]. Lactating mothers should also avoid this medication due to the potential risk it poses to infants.

Conclusion[edit]

Miltefosine heralds a new era in the treatment of leishmaniasis and certain amoebic infections. As the medical landscape continues its evolution, the balance between this drug's therapeutic potential and its associated risks becomes ever more critical, ensuring both patient safety and effective outcomes.

References[edit]

↑ Sundar, S., & Chakravarty, J. (2015). Leishmaniasis: An update of current pharmacotherapy. Expert Opinion on Pharmacotherapy, 16(2), 237-252.
↑ Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., ... & Boelaert, M. (2007). Visceral leishmaniasis: What are the needs for diagnosis, treatment, and control? Nature Reviews Microbiology, 5(11), S7-S16.
↑ Grace, E., Asbill, S., & Virga, K. (2015). Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrobial Agents and Chemotherapy, 59(11), 6677-6681.
↑ Dorlo, T. P., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012). Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy, 67(11), 2576-2597.
↑ Rijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N. R., Dorlo, T. P., ... & Boelaert, M. (2013). Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases, 56(11), 1530-1538.
↑ Dorlo, T. P., Huitema, A. D., Beijnen, J. H., & de Vries, P. J. (2012). Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 56(7), 3864-3872.

[1] Sundar, S., & Chakravarty, J. (2015). Leishmaniasis: An update of current pharmacotherapy. Expert Opinion on Pharmacotherapy, 16(2), 237-252.

[2] Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., ... & Boelaert, M. (2007). Visceral leishmaniasis: What are the needs for diagnosis, treatment, and control? Nature Reviews Microbiology, 5(11), S7-S16.

[3] Grace, E., Asbill, S., & Virga, K. (2015). Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrobial Agents and Chemotherapy, 59(11), 6677-6681.

[4] Dorlo, T. P., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012). Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. Journal of Antimicrobial Chemotherapy, 67(11), 2576-2597.

[5] Rijal, S., Ostyn, B., Uranw, S., Rai, K., Bhattarai, N. R., Dorlo, T. P., ... & Boelaert, M. (2013). Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clinical Infectious Diseases, 56(11), 1530-1538.

[6] Dorlo, T. P., Huitema, A. D., Beijnen, J. H., & de Vries, P. J. (2012). Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 56(7), 3864-3872.

[1]

[2]

[3]

[4]

[5]

[6]